DEF 14A: Aclarion, Inc. Seeks Stockholder Approval for Key Proposals at 2024 Annual Meeting

Aclarion, Inc. is holding its 2024 Annual Meeting of Stockholders on December 31, 2024, to vote on several key proposals, including the election of directors, ratification of auditors, and approval of stock issuances and a reverse stock split.

Summary

• Aclarion, Inc. will hold its 2024 Annual Meeting of Stockholders on December 31, 2024, to vote on several key proposals.
• The proposals include the election of seven director nominees, ratification of Haynie & Company as the independent auditor, and authorization for the issuance of common stock related to an amended Equity Line of Credit (ELOC).
• Stockholders will also vote on authorizing the issuance of common stock related to Series B and Series C convertible preferred stock issued to private investors.
• A significant proposal is to grant the board discretionary authority to implement a reverse stock split within a range of 1-for-5 to 1-for-400.
• Additionally, stockholders will vote on an amendment to the company's 2022 Equity Incentive Plan.
• The board of directors recommends voting in favor of all proposals.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The company is actively seeking funding and taking steps to maintain its listing, but there are also risks associated with dilution and potential stock price volatility. The sentiment is neutral to slightly positive, reflecting the necessary but potentially risky actions being taken.

Positives

• Extending the Equity Line of Credit with White Lion Capital provides the company with additional financial flexibility.
• The proposed reverse stock split could make the company's stock more attractive to institutional investors and help maintain Nasdaq listing compliance.
• Increasing the share reserve and annual grant limit of the 2022 Equity Incentive Plan will improve the company's ability to attract and retain key personnel.
• The company has secured additional funding through the Series B and Series C preferred stock financings.

Negatives

• The issuance of shares related to the ELOC, Series B, and Series C preferred stock will dilute existing stockholders' ownership.
• The reverse stock split could negatively impact the stock price and liquidity.
• The company has had issues with maintaining the minimum bid price on the Nasdaq Capital Market.
• The company has had multiple changes in its independent registered public accounting firm in the past two years.

Risks

• The company's stock price may be negatively impacted by the reverse stock split and the issuance of new shares.
• There is no guarantee that the reverse stock split will result in a sustained increase in the stock price or maintain Nasdaq listing compliance.
• The company's ability to raise additional capital through the Equity Line of Credit depends on market conditions and White Lion Capital's willingness to purchase shares.
• The conversion of preferred stock and exercise of warrants could lead to further dilution of existing shareholders.
• The company has a history of material weaknesses in its internal control over financial reporting.

Future Outlook

The company intends to use the proceeds from the Equity Line of Credit and preferred stock financings for general corporate purposes, including working capital. The company also intends to implement a reverse stock split to maintain Nasdaq listing compliance.

Management Comments

• The board believes that extending the term of the Purchase Agreement will enhance the Company's ability to raise additional capital over the coming year.
• The board believes that the current 195,695 share reserve will limit the Company's ability to grant equity to employees, officers and other key personnel in the amounts necessary to provide appropriate incentives.
• The board believes that increasing the size of the share reserve of the 2022 Plan will improve the Company's ability to grant appropriate and attractive equity incentive to key personnel.

Industry Context

The proposals reflect Aclarion's efforts to secure funding and maintain its listing on the Nasdaq Capital Market, which is common for companies in the medical technology sector. The use of equity lines of credit and convertible preferred stock is a typical financing strategy for companies in this stage of development.

Comparison to Industry Standards

• The use of an equity line of credit is a common financing tool for small-cap and micro-cap companies, particularly in the biotech and medical device sectors, where capital needs are high and revenue generation can be unpredictable. Companies like Aclarion often use these facilities to access capital quickly and flexibly.
• The proposed reverse stock split is a measure often taken by companies facing delisting from major exchanges due to low share prices. This is a common strategy to regain compliance with minimum bid price requirements, as seen with other companies in similar situations.
• The use of convertible preferred stock is a standard method for raising capital from private investors, offering them a combination of income and potential equity upside. This is a common practice in the venture capital and private equity markets.
• The proposed increase in the share reserve and annual grant limits of the 2022 Equity Incentive Plan is consistent with the need to attract and retain talent in competitive industries. Many companies in the tech and biotech sectors use equity compensation as a key component of their overall compensation strategy.

Related Party Transactions

• Since January 2020, the company paid a total of $125,324 to the Regents of the University of California pursuant to a License Agreement.
• The company has entered into a number of investment and commercial transactions with Nuvasive, Inc.
• Since January 2019, SC Capital 1 LLC and Clark Gunderson, M.D. have invested in the company's Series B-1 preferred stock financing and 6% convertible preferred note financing.
• On February 16, 2023, the company entered into a securities purchase agreement with Jeffrey Thramann, our Executive Chairman pursuant to which we issued and sold one (1) share of the Company's newly designated Series A Preferred Stock for an aggregate purchase price of $1,000.

Stakeholder Impact

• Existing stockholders will experience dilution due to the issuance of new shares.
• The reverse stock split could impact the stock price and liquidity, affecting both current and potential investors.
• Employees and consultants may benefit from the increased equity compensation opportunities.
• The company's ability to secure funding and maintain its Nasdaq listing will impact its long-term viability and value for all stakeholders.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on December 31, 2024.
• The board will determine the specific ratio for the reverse stock split if approved by stockholders.
• The company will continue to seek funding through the Equity Line of Credit and other means.
• The company will implement the amendment to the 2022 Equity Incentive Plan if approved by stockholders.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Reverse Stock Split, Equity Line of Credit, Preferred Stock, Stock Issuance, Haynie & Company, Equity Incentive Plan, Nasdaq, Director Election